Overview
Severe phosphoribosylpyrophosphate (PRPP) synthetase superactivity is a rare inherited metabolic disorder that causes the body to produce too much uric acid. The condition is caused by an overactive form of the enzyme PRPP synthetase, which plays a key role in making purines — the building blocks of DNA and RNA. When this enzyme works too hard, the body creates excess purines, which are then broken down into uric acid. This buildup of uric acid can cause serious problems throughout the body, especially in the kidneys and nervous system. In the severe form of this disease, symptoms typically begin in infancy or early childhood and can include kidney stones, kidney failure, gout (painful joint swelling), developmental delay, intellectual disability, hearing loss, and low muscle tone (hypotonia). Some children may also experience seizures and difficulty with movement. The neurological problems in the severe form set it apart from the milder version of PRPP synthetase superactivity, which mainly causes gout and kidney stones in adulthood. Treatment focuses on lowering uric acid levels in the body, primarily using a medication called allopurinol. While this drug can help prevent kidney damage and gout attacks, it does not reverse the neurological problems that may already be present. Early diagnosis and treatment are important to protect kidney function and reduce complications. Supportive therapies such as physical therapy, hearing aids, and special education services may also be needed depending on the child's symptoms.
Key symptoms:
Kidney stonesKidney failureGout (painful, swollen joints)Hearing loss or deafnessIntellectual disabilityDevelopmental delayLow muscle tone (floppiness)SeizuresDifficulty with coordination and movementHigh uric acid levels in blood and urineOrange or reddish crystals in diapers (urate crystals)Failure to thriveSpeech delaySelf-injurious behavior in some cases
Clinical phenotype terms (21)— hover any for plain English
X-linked recessive
Carried on the X chromosome; typically affects males more than females
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
1 availableAurlumyn
AURLUMYN is indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations
Clinical Trials
View all trials with filters →No actively recruiting trials found for Severe phosphoribosylpyrophosphate synthetase superactivity at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Severe phosphoribosylpyrophosphate synthetase superactivity.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Severe phosphoribosylpyrophosphate synthetase superactivity.
Community
No community posts yet. Be the first to share your experience with Severe phosphoribosylpyrophosphate synthetase superactivity.
Start the conversation →Latest news about Severe phosphoribosylpyrophosphate synthetase superactivity
No recent news articles for Severe phosphoribosylpyrophosphate synthetase superactivity.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How severe is my child's condition compared to other cases, and what symptoms should I expect over time?,What is the current uric acid level, and is the allopurinol dose adequate to control it?,How often should kidney function and hearing be tested?,Are there any clinical trials or new treatments being studied for this condition?,What therapies (physical, speech, occupational) would benefit my child the most right now?,Should other family members be tested, especially females who might be carriers?,What dietary changes should we make, and should we see a dietitian?
Common questions about Severe phosphoribosylpyrophosphate synthetase superactivity
What is Severe phosphoribosylpyrophosphate synthetase superactivity?
Severe phosphoribosylpyrophosphate (PRPP) synthetase superactivity is a rare inherited metabolic disorder that causes the body to produce too much uric acid. The condition is caused by an overactive form of the enzyme PRPP synthetase, which plays a key role in making purines — the building blocks of DNA and RNA. When this enzyme works too hard, the body creates excess purines, which are then broken down into uric acid. This buildup of uric acid can cause serious problems throughout the body, especially in the kidneys and nervous system. In the severe form of this disease, symptoms typically b
How is Severe phosphoribosylpyrophosphate synthetase superactivity inherited?
Severe phosphoribosylpyrophosphate synthetase superactivity follows a x-linked recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Severe phosphoribosylpyrophosphate synthetase superactivity typically begin?
Typical onset of Severe phosphoribosylpyrophosphate synthetase superactivity is infantile. Age of onset can vary across affected individuals.
What treatment and support options exist for Severe phosphoribosylpyrophosphate synthetase superactivity?
1 patient support program are currently tracked on UniteRare for Severe phosphoribosylpyrophosphate synthetase superactivity. See the treatments and support programs sections for copay assistance, eligibility, and contact details.